Butyrylcholinesterase Levels on Admission Predict Severity and 12-Month Mortality in Hospitalized AIDS Patients
Background. Butyrylcholinesterase (BChE) is synthesized mainly in the liver and an important marker in many infectious/inflammatory diseases, but its role in acquired immunodeficiency syndrome (AIDS) patients is not clear. We wished to ascertain if BChE level is associated with the progression/progn...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2018-01-01
|
Series: | Mediators of Inflammation |
Online Access: | http://dx.doi.org/10.1155/2018/5201652 |
id |
doaj-924cb1895fdd461abf9e577a63fca4f6 |
---|---|
record_format |
Article |
spelling |
doaj-924cb1895fdd461abf9e577a63fca4f62020-11-24T23:13:03ZengHindawi LimitedMediators of Inflammation0962-93511466-18612018-01-01201810.1155/2018/52016525201652Butyrylcholinesterase Levels on Admission Predict Severity and 12-Month Mortality in Hospitalized AIDS PatientsLijun Xu0Biao Zhu1Ying Huang2Zongxing Yang3Jia Sun4Yan Xu5Jinlei Zheng6Sabine Kinloch7Michael T. Yin8Honglei Weng9Nanping Wu10The State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Qingchun Rd, Hangzhou, ChinaThe State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Qingchun Rd, Hangzhou, ChinaThe State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Qingchun Rd, Hangzhou, ChinaThe State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Qingchun Rd, Hangzhou, ChinaThe State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Qingchun Rd, Hangzhou, ChinaThe State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Qingchun Rd, Hangzhou, ChinaZhejiang Provincial Center for Disease Control and Prevention, Xincheng Rd, Hangzhou, ChinaDepartment of HIV Medicine, Royal Free Hospital, Pond Street, London, UKDivision of Infectious Diseases, Columbia University Medical Center, New York, NY, USADepartment of Medicine II, Section Molecular Hepatology, Medical Faculty Mannheim, Heidelberg University, Mannheim, GermanyThe State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Qingchun Rd, Hangzhou, ChinaBackground. Butyrylcholinesterase (BChE) is synthesized mainly in the liver and an important marker in many infectious/inflammatory diseases, but its role in acquired immunodeficiency syndrome (AIDS) patients is not clear. We wished to ascertain if BChE level is associated with the progression/prognosis of AIDS patients. Methods. BChE levels (in U/L) were measured in 505 patients; <4500 was defined as “low” and ≥4500 as “normal.” Associations between BChE level and CD4 count, WHO stage, body mass index (BMI), C-reactive protein (CRP) level, and duration of hospitalization were assessed. Kaplan–Meier curves and Cox proportional hazards model were used to assess associations between low BChE levels and mortality, after adjustment for age, CD4 count, WHO stage, and laboratory parameters. Results. A total of 129 patients (25.5%) had a lower BChE level. BChE was closely associated with CD4 count, WHO stage, CRP level, and BMI (all P<0.001). Eighty-four patients (16.6%) died in the first year of follow-up. One-year survival was 64.5 ± 4.5% for patients with low BChE and 87.6 ± 1.8% for those with normal BChE (log-rank, P<0.001). After adjustment for sex, age, BMI, WHO stage, and CD4 count, as well as serum levels of hemoglobin, sodium, and albumin, the hazard ratio was 1.8 (95% confidence interval, 1.0–3.2) for patients with a low BChE compared with those with a normal BChE (P=0.035). Conclusion. BChE level is associated with HIV/AIDS severity and is an independent risk factor for increased mortality in AIDS patients.http://dx.doi.org/10.1155/2018/5201652 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lijun Xu Biao Zhu Ying Huang Zongxing Yang Jia Sun Yan Xu Jinlei Zheng Sabine Kinloch Michael T. Yin Honglei Weng Nanping Wu |
spellingShingle |
Lijun Xu Biao Zhu Ying Huang Zongxing Yang Jia Sun Yan Xu Jinlei Zheng Sabine Kinloch Michael T. Yin Honglei Weng Nanping Wu Butyrylcholinesterase Levels on Admission Predict Severity and 12-Month Mortality in Hospitalized AIDS Patients Mediators of Inflammation |
author_facet |
Lijun Xu Biao Zhu Ying Huang Zongxing Yang Jia Sun Yan Xu Jinlei Zheng Sabine Kinloch Michael T. Yin Honglei Weng Nanping Wu |
author_sort |
Lijun Xu |
title |
Butyrylcholinesterase Levels on Admission Predict Severity and 12-Month Mortality in Hospitalized AIDS Patients |
title_short |
Butyrylcholinesterase Levels on Admission Predict Severity and 12-Month Mortality in Hospitalized AIDS Patients |
title_full |
Butyrylcholinesterase Levels on Admission Predict Severity and 12-Month Mortality in Hospitalized AIDS Patients |
title_fullStr |
Butyrylcholinesterase Levels on Admission Predict Severity and 12-Month Mortality in Hospitalized AIDS Patients |
title_full_unstemmed |
Butyrylcholinesterase Levels on Admission Predict Severity and 12-Month Mortality in Hospitalized AIDS Patients |
title_sort |
butyrylcholinesterase levels on admission predict severity and 12-month mortality in hospitalized aids patients |
publisher |
Hindawi Limited |
series |
Mediators of Inflammation |
issn |
0962-9351 1466-1861 |
publishDate |
2018-01-01 |
description |
Background. Butyrylcholinesterase (BChE) is synthesized mainly in the liver and an important marker in many infectious/inflammatory diseases, but its role in acquired immunodeficiency syndrome (AIDS) patients is not clear. We wished to ascertain if BChE level is associated with the progression/prognosis of AIDS patients. Methods. BChE levels (in U/L) were measured in 505 patients; <4500 was defined as “low” and ≥4500 as “normal.” Associations between BChE level and CD4 count, WHO stage, body mass index (BMI), C-reactive protein (CRP) level, and duration of hospitalization were assessed. Kaplan–Meier curves and Cox proportional hazards model were used to assess associations between low BChE levels and mortality, after adjustment for age, CD4 count, WHO stage, and laboratory parameters. Results. A total of 129 patients (25.5%) had a lower BChE level. BChE was closely associated with CD4 count, WHO stage, CRP level, and BMI (all P<0.001). Eighty-four patients (16.6%) died in the first year of follow-up. One-year survival was 64.5 ± 4.5% for patients with low BChE and 87.6 ± 1.8% for those with normal BChE (log-rank, P<0.001). After adjustment for sex, age, BMI, WHO stage, and CD4 count, as well as serum levels of hemoglobin, sodium, and albumin, the hazard ratio was 1.8 (95% confidence interval, 1.0–3.2) for patients with a low BChE compared with those with a normal BChE (P=0.035). Conclusion. BChE level is associated with HIV/AIDS severity and is an independent risk factor for increased mortality in AIDS patients. |
url |
http://dx.doi.org/10.1155/2018/5201652 |
work_keys_str_mv |
AT lijunxu butyrylcholinesteraselevelsonadmissionpredictseverityand12monthmortalityinhospitalizedaidspatients AT biaozhu butyrylcholinesteraselevelsonadmissionpredictseverityand12monthmortalityinhospitalizedaidspatients AT yinghuang butyrylcholinesteraselevelsonadmissionpredictseverityand12monthmortalityinhospitalizedaidspatients AT zongxingyang butyrylcholinesteraselevelsonadmissionpredictseverityand12monthmortalityinhospitalizedaidspatients AT jiasun butyrylcholinesteraselevelsonadmissionpredictseverityand12monthmortalityinhospitalizedaidspatients AT yanxu butyrylcholinesteraselevelsonadmissionpredictseverityand12monthmortalityinhospitalizedaidspatients AT jinleizheng butyrylcholinesteraselevelsonadmissionpredictseverityand12monthmortalityinhospitalizedaidspatients AT sabinekinloch butyrylcholinesteraselevelsonadmissionpredictseverityand12monthmortalityinhospitalizedaidspatients AT michaeltyin butyrylcholinesteraselevelsonadmissionpredictseverityand12monthmortalityinhospitalizedaidspatients AT hongleiweng butyrylcholinesteraselevelsonadmissionpredictseverityand12monthmortalityinhospitalizedaidspatients AT nanpingwu butyrylcholinesteraselevelsonadmissionpredictseverityand12monthmortalityinhospitalizedaidspatients |
_version_ |
1725599623843676160 |